Marcel Seungsu Woo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcel Seungsu Woo has a total of 508 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Alexander Friese
Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
26 shared publications - Pedro Rosa-Neto
Montreal Neurological Institute, McGill University Health Centre, Montréal, Québec, Canada
16 shared publications Nesrine Rahmouni
Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre (BIC), Montreal Neurological Institute, Montréal, Quebec, Canada
14 shared publicationsSerge Gauthier
Department of Neurology and Neurosurgery, McGill University , Montreal, Quebec H3A 1A1
14 shared publications- Christina Mayer
Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
11 shared publications Gassan Massarweh
Montreal Neurological Institute, Montreal, Quebec, Canada
11 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (45)
CD8 + T cells induce RIPK1-regulated brain endothelial cell death in cerebral malaria
Cerebral malaria (CM) is a potentially lethal complication of Plasmodium falciparum infection characterized by blood-brain barrier disruption and brain hemorrhage. Although immune-mediated endothelial damage is central to CM pathology, the mechanisms linking cytotoxic immune responses to endothelial injury remain unclear. Here, we show that CD8 + T cells induce receptor-interacting serine/threonine-protein kinase 1 (RIPK1)–regulated cell death of brain endothelial cells in mouse CM, while RIPK1 phosphorylation is increased in brain endothelial cells in human CM. Using magnetic resonance imaging, three-dimensional tissue-cleared brain imaging, cross-species pathology, endothelial translatomics, immunocerebrovascular interactomics, and genetic association testing, we identify a CD8 + T cell–dependent, RIPK1-centered mouse endothelial cell death program. Combined RIPK1 and caspase inhibition protected cross-presenting endothelial cells from CD8 + T cell–mediated death in vitro. In vivo, brain endothelial-specific genetic inactivation or systemic pharmacological inhibition of RIPK1 kinase activity prolonged survival in mouse CM without altering parasitemia. These findings support RIPK1 inhibition as a promising therapeutic strategy to counter CD8 + T cell–induced endothelial death in CM.
- 6 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (45)
Open AccessCD8 + T cells induce RIPK1-regulated brain endothelial cell death in cerebral malaria
Cerebral malaria (CM) is a potentially lethal complication of Plasmodium falciparum infection characterized by blood-brain barrier disruption and brain hemorrhage. Although immune-mediated endothelial damage is central to CM pathology, the mechanisms linking cytotoxic immune responses to endothelial injury remain unclear. Here, we show that CD8 + T cells induce receptor-interacting serine/threonine-protein kinase 1 (RIPK1)–regulated cell death of brain endothelial cells in mouse CM, while RIPK1 phosphorylation is increased in brain endothelial cells in human CM. Using magnetic resonance imaging, three-dimensional tissue-cleared brain imaging, cross-species pathology, endothelial translatomics, immunocerebrovascular interactomics, and genetic association testing, we identify a CD8 + T cell–dependent, RIPK1-centered mouse endothelial cell death program. Combined RIPK1 and caspase inhibition protected cross-presenting endothelial cells from CD8 + T cell–mediated death in vitro. In vivo, brain endothelial-specific genetic inactivation or systemic pharmacological inhibition of RIPK1 kinase activity prolonged survival in mouse CM without altering parasitemia. These findings support RIPK1 inhibition as a promising therapeutic strategy to counter CD8 + T cell–induced endothelial death in CM.
- Open Access
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8136) , 765-773
Intracellular complement factor H protects neurons during CNS inflammation
Neurodegeneration is a major driver of disability in multiple sclerosis (MS), the most common chronic inflammatory disease of the central nervous system (CNS) 1 . Retinal ganglion cells (RGCs), a heterogeneous neuronal population in the eye, undergo degeneration in MS and provide a model to study neuronal subtype-specific resilience to inflammatory injury 2 . However, the neuron-intrinsic mechanisms underlying differential vulnerability remain unclear. Here we identify a neuroprotective role for intracellular complement factor H (CFH) in neurons. Using single-nucleus RNA-sequencing analysis of RGCs from donors with MS and control individuals, we found that CFH expression was strongly correlated with intrinsic resilience to RGC degeneration. Mechanistically, CFH was induced in retinal and other CNS neurons in response to inflammatory and oxidative stress, where it limited reactive oxygen species accumulation and lipid peroxidation. CFH localized to the endoplasmic reticulum, a major site of lipid peroxidation during neuronal ferroptosis. Its protective activity was dependent on its C-terminal SCR20 domain, was independent of CFH secretion and was preserved in the absence of complement component C3. These findings reveal a non-canonical intracellular function of CFH in neurons. Together, our results identify CFH as a key mediator of neuronal resilience across the CNS in mice and humans and provide mechanistic insight into inflammatory neurodegeneration with implications for MS therapy and neuroprotection more broadly.
- 2 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8136) , 765-773
Open AccessIntracellular complement factor H protects neurons during CNS inflammation
Neurodegeneration is a major driver of disability in multiple sclerosis (MS), the most common chronic inflammatory disease of the central nervous system (CNS) 1 . Retinal ganglion cells (RGCs), a heterogeneous neuronal population in the eye, undergo degeneration in MS and provide a model to study neuronal subtype-specific resilience to inflammatory injury 2 . However, the neuron-intrinsic mechanisms underlying differential vulnerability remain unclear. Here we identify a neuroprotective role for intracellular complement factor H (CFH) in neurons. Using single-nucleus RNA-sequencing analysis of RGCs from donors with MS and control individuals, we found that CFH expression was strongly correlated with intrinsic resilience to RGC degeneration. Mechanistically, CFH was induced in retinal and other CNS neurons in response to inflammatory and oxidative stress, where it limited reactive oxygen species accumulation and lipid peroxidation. CFH localized to the endoplasmic reticulum, a major site of lipid peroxidation during neuronal ferroptosis. Its protective activity was dependent on its C-terminal SCR20 domain, was independent of CFH secretion and was preserved in the absence of complement component C3. These findings reveal a non-canonical intracellular function of CFH in neurons. Together, our results identify CFH as a key mediator of neuronal resilience across the CNS in mice and humans and provide mechanistic insight into inflammatory neurodegeneration with implications for MS therapy and neuroprotection more broadly.
- Open Access
- 14 July 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (7) , 1468-1481
Spatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts.
This longitudinal study including four independent cohorts assessed the spatiotemporal dynamics of tau extent and load changes in Alzheimer's disease using tau positron emission tomography data from 2,459 participants, including 898 followed for up to 7 years. Regional standardized uptake value ratios indexed tau load, whereas the spatial extent of tauopathy (SEOT) (proportion of abnormal voxels) measured tau extent. We observed burden-dependent longitudinal dynamics of tau progression: SEOT showed greater sensitivity to increases over time in regions with low baseline tau burden, whereas the standardized uptake value ratio was more informative for tracking accumulation once regional burden was established. This pattern was consistent across Braak regions and cohorts and was reflected in differential associations with other Alzheimer's disease severity markers. These findings refine models of tau propagation by suggesting that tau positron emission tomography changes may be differentially captured by extent-based and load-based metrics at different stages of disease progression, highlighting SEOT as a promising surrogate outcome for trials.
- 14 July 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (7) , 1468-1481
Open AccessSpatiotemporal dynamics of tau extent and load increase in Alzheimer's disease across four longitudinal cohorts.
This longitudinal study including four independent cohorts assessed the spatiotemporal dynamics of tau extent and load changes in Alzheimer's disease using tau positron emission tomography data from 2,459 participants, including 898 followed for up to 7 years. Regional standardized uptake value ratios indexed tau load, whereas the spatial extent of tauopathy (SEOT) (proportion of abnormal voxels) measured tau extent. We observed burden-dependent longitudinal dynamics of tau progression: SEOT showed greater sensitivity to increases over time in regions with low baseline tau burden, whereas the standardized uptake value ratio was more informative for tracking accumulation once regional burden was established. This pattern was consistent across Braak regions and cohorts and was reflected in differential associations with other Alzheimer's disease severity markers. These findings refine models of tau propagation by suggesting that tau positron emission tomography changes may be differentially captured by extent-based and load-based metrics at different stages of disease progression, highlighting SEOT as a promising surrogate outcome for trials.
- Open Access
- 21 May 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (5) , 1051-1066
The exercise hormone irisin has neuroprotective effects in a mouse model of multiple sclerosis
Aerobic exercise is a disease-modifying intervention in multiple sclerosis (MS) that ameliorates several progressive neurological symptoms in people with MS. Here we show that the exercise hormone irisin mediates neuroprotective effects of exercise in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. We demonstrate that voluntary free-wheel running exercise protects against inflammation-induced neurodegeneration in EAE, but these neuroprotective effects are abrogated in mice lacking Fndc5 /irisin. Peripheral delivery of irisin increases irisin plasma levels and reduces both clinical symptoms and neuronal loss in EAE. Although peripheral irisin does not alter peripheral and central immune responses in EAE, it induces a direct neuroprotective gene programme in spinal cord neurons and preserves synapses and mitochondrial activity, probably through direct binding to motor neurons. Taken together, these findings suggest that irisin induction in response to exercise confers direct neuroprotective effects in an inflammation-driven neurodegenerative condition, making it an attractive therapeutic candidate for MS.
- 21 May 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (5) , 1051-1066
Open AccessThe exercise hormone irisin has neuroprotective effects in a mouse model of multiple sclerosis
Aerobic exercise is a disease-modifying intervention in multiple sclerosis (MS) that ameliorates several progressive neurological symptoms in people with MS. Here we show that the exercise hormone irisin mediates neuroprotective effects of exercise in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. We demonstrate that voluntary free-wheel running exercise protects against inflammation-induced neurodegeneration in EAE, but these neuroprotective effects are abrogated in mice lacking Fndc5 /irisin. Peripheral delivery of irisin increases irisin plasma levels and reduces both clinical symptoms and neuronal loss in EAE. Although peripheral irisin does not alter peripheral and central immune responses in EAE, it induces a direct neuroprotective gene programme in spinal cord neurons and preserves synapses and mitochondrial activity, probably through direct binding to motor neurons. Taken together, these findings suggest that irisin induction in response to exercise confers direct neuroprotective effects in an inflammation-driven neurodegenerative condition, making it an attractive therapeutic candidate for MS.
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214606
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum
Neurofibrillary tangles (NFTs) progressively damage gray matter in Alzheimer disease (AD). Resulting cortical microstructural alterations might not be detectable using macrostructural metrics but may be studied using isotropic water diffusion, as it reflects extracellular free water content. The aim of this study was to examine the effect of NFTs on cortical microstructure by investigating whether cortical free water increases as a function of tau load. We also investigated whether phosphorylated tau in blood plasma also indicated cortical microstructural abnormalities. For this cross-sectional study, we sampled participants with T1 MRI, multishell diffusion-weighted MRI, amyloid PET ([18F]AZD4694), tau PET, and plasma phosphorylated tau 217+ (p-tau217) from the Translational biomarkers in Aging and Dementia cohort at McGill University; participants were recruited between 2017 and 2024. We used the Neurite Orientation Dispersion and Density Imaging algorithm to calculate isotropic free water images ("free water"). FreeSurfer was used to calculate cortical thickness in the entorhinal, fusiform, inferior temporal, and middle temporal gyri regions of interest ("meta-ROI"); Automatic Segmentation of Hippocampal Subfields was used to calculate hippocampal volumes. We grouped participants by amyloid PET positivity (A), plasma p-tau217 positivity (T1), and tau PET positivity (T2). We performed voxel-wise correlation analyses between free water and these proteinopathy markers, as well as ROI-based analyses in the meta-ROI. A total of 303 participants (mean age 67 years, 58.7% female) were included in this study (168 cognitively normal individuals, 43 with mild cognitive impairment, 23 with AD dementia, 68 not diagnosed). Tau PET was positively correlated with free water in gray matter predominantly in the temporal lobe (partial R2 = 0.39, p < 0.001), and the correlation of p-tau217 with the meta-ROI free water was entirely mediated by tau PET (p < 0.001). In addition, medial temporal and hippocampal free water was negatively correlated with Montreal Cognitive Assessment scores in the A-T1+ and A+T2+ groups. The strongest ROI-based multilinear models for predicting temporal gray matter and hippocampal tau PET burden used both cortical thickness and free water as predictors (temporal gray matter partial R2 = 0.62; hippocampal partial R2 = 0.64). In AD-relevant regions, increased free water correlates with tau load independently of macrostructural metrics or amyloid load. Free water may serve as an imaging marker for microstructural changes in gray matter resulting from NFT accumulation, complementary to macrostructural metrics.
- 10 March 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (5) , e214606
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease Continuum
Neurofibrillary tangles (NFTs) progressively damage gray matter in Alzheimer disease (AD). Resulting cortical microstructural alterations might not be detectable using macrostructural metrics but may be studied using isotropic water diffusion, as it reflects extracellular free water content. The aim of this study was to examine the effect of NFTs on cortical microstructure by investigating whether cortical free water increases as a function of tau load. We also investigated whether phosphorylated tau in blood plasma also indicated cortical microstructural abnormalities. For this cross-sectional study, we sampled participants with T1 MRI, multishell diffusion-weighted MRI, amyloid PET ([18F]AZD4694), tau PET, and plasma phosphorylated tau 217+ (p-tau217) from the Translational biomarkers in Aging and Dementia cohort at McGill University; participants were recruited between 2017 and 2024. We used the Neurite Orientation Dispersion and Density Imaging algorithm to calculate isotropic free water images ("free water"). FreeSurfer was used to calculate cortical thickness in the entorhinal, fusiform, inferior temporal, and middle temporal gyri regions of interest ("meta-ROI"); Automatic Segmentation of Hippocampal Subfields was used to calculate hippocampal volumes. We grouped participants by amyloid PET positivity (A), plasma p-tau217 positivity (T1), and tau PET positivity (T2). We performed voxel-wise correlation analyses between free water and these proteinopathy markers, as well as ROI-based analyses in the meta-ROI. A total of 303 participants (mean age 67 years, 58.7% female) were included in this study (168 cognitively normal individuals, 43 with mild cognitive impairment, 23 with AD dementia, 68 not diagnosed). Tau PET was positively correlated with free water in gray matter predominantly in the temporal lobe (partial R2 = 0.39, p < 0.001), and the correlation of p-tau217 with the meta-ROI free water was entirely mediated by tau PET (p < 0.001). In addition, medial temporal and hippocampal free water was negatively correlated with Montreal Cognitive Assessment scores in the A-T1+ and A+T2+ groups. The strongest ROI-based multilinear models for predicting temporal gray matter and hippocampal tau PET burden used both cortical thickness and free water as predictors (temporal gray matter partial R2 = 0.62; hippocampal partial R2 = 0.64). In AD-relevant regions, increased free water correlates with tau load independently of macrostructural metrics or amyloid load. Free water may serve as an imaging marker for microstructural changes in gray matter resulting from NFT accumulation, complementary to macrostructural metrics.
- Open Access
- 8 March 2026
- Published by Springer Nature in Research Square
Aβ-related Cerebrospinal Fluid Proteins in Alzheimer’s Disease Reflect Gene Expression Levels Found in The Healthy Cortex
A growing body of evidence indicates that CSF proteomic signatures shift with increasing brain amyloidosis in Alzheimer’s disease (AD). However, it remains unknown whether protein profiles within cortical regions that are vulnerable to early amyloid-beta (Aβ) deposition contribute to, or predict, CSF Aβ-related protein measures. To address this question, we examined 220 cognitively unimpaired (CU) and cognitively impaired (CI) older participants from the TRIAD cohort who had Aβ- and tau-PET scans, MRI, and CSF NULISA™seq CNS panel data. Aβ-related hierarchical clustering identified 12 clusters corresponding to biologically interpretable gene ontology processes, supported by bootstrap resampling, silhouette analysis, and dynamic tree cutting. Clusters’ composite scores for tau-markers, neuronal-injury, and APOE4 correlated strongly with global neocortical Aβ-PET SUVR (p < 0.001) and showed elevated odds ratios (OR) of Aβ positivity (ORs: 10.4, 2.4, and 4.0, respectively). The Aβ42 cluster, as expected, was inversely associated with brain Aβ burden and predicted reduced Aβ positivity (OR = 0.13). Voxel-wise analyses revealed distinct spatial signatures for each cluster, such as associations in cortical regions (tau-markers, neuronal-injury, and APOE4 clusters), white matter (axonal metabolic injury cluster), and periventricular areas (synaptic signaling and cellular response clusters). The magnitude of Aβ-related cortical associations and CSF protein clusters correlated with the magnitude of regional mRNA expression derived from the Allen Brain Atlas. Our findings support the notion that CSF protein expression reflects underlying regional mRNA expression in cortical regions vulnerable to AD pathophysiology.
- 8 March 2026
- Published by Springer Nature in Research Square
Open AccessAβ-related Cerebrospinal Fluid Proteins in Alzheimer’s Disease Reflect Gene Expression Levels Found in The Healthy Cortex
A growing body of evidence indicates that CSF proteomic signatures shift with increasing brain amyloidosis in Alzheimer’s disease (AD). However, it remains unknown whether protein profiles within cortical regions that are vulnerable to early amyloid-beta (Aβ) deposition contribute to, or predict, CSF Aβ-related protein measures. To address this question, we examined 220 cognitively unimpaired (CU) and cognitively impaired (CI) older participants from the TRIAD cohort who had Aβ- and tau-PET scans, MRI, and CSF NULISA™seq CNS panel data. Aβ-related hierarchical clustering identified 12 clusters corresponding to biologically interpretable gene ontology processes, supported by bootstrap resampling, silhouette analysis, and dynamic tree cutting. Clusters’ composite scores for tau-markers, neuronal-injury, and APOE4 correlated strongly with global neocortical Aβ-PET SUVR (p < 0.001) and showed elevated odds ratios (OR) of Aβ positivity (ORs: 10.4, 2.4, and 4.0, respectively). The Aβ42 cluster, as expected, was inversely associated with brain Aβ burden and predicted reduced Aβ positivity (OR = 0.13). Voxel-wise analyses revealed distinct spatial signatures for each cluster, such as associations in cortical regions (tau-markers, neuronal-injury, and APOE4 clusters), white matter (axonal metabolic injury cluster), and periventricular areas (synaptic signaling and cellular response clusters). The magnitude of Aβ-related cortical associations and CSF protein clusters correlated with the magnitude of regional mRNA expression derived from the Allen Brain Atlas. Our findings support the notion that CSF protein expression reflects underlying regional mRNA expression in cortical regions vulnerable to AD pathophysiology.
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (2)
Ventricular enlargement is associated with early Alzheimer’s disease pathophysiology
Alzheimer’s disease (AD) is characterized by progressive brain changes, including protein aggregation and structural changes. Cerebrospinal fluid (CSF) system abnormalities, such as ventricular dilation, increased choroid plexus volume or positron emission tomography (PET) ligand uptake in the CSF, have also been consistently described. We aimed to examine whether changes in CSF production and clearance might be associated with brain protein aggregation across biological stages of Alzheimer’s disease. We hypothesized an association between brain protein aggregation and changes on the CSF system. We examined 378 individuals from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort with T1-weighted magnetic resonance imaging (MRI), amyloid-PET and tau-PET assessments. We assessed the lateral ventricle and choroid plexus volumes, both corrected for intracranial volume, in the MRI native space. Non-specific ventricular tracer standardized uptake value ratio (SUVR), derived from amyloid- and tau-PET images, was used as an indirect marker of choroid plexus-related clearance activity and served as a metric of CSF dynamics. Linear models tested associations amongst lateral ventricular volume (reflecting CSF space enlargement), choroid plexus volume (reflecting secretory tissue morphology) and ventricular SUVR (reflecting tracer activity within the CSF compartment and serving as an indirect marker of choroid plexus-related clearance function and CSF dynamics) with Aβ and tau aggregations. Analyses were restricted to within-modality associations, relating ventricular radioactivity to cortical pathology for each PET tracer. We found that when considered independently, larger ventricular and choroid plexus volumes were associated with higher neocortical Aβ-PET SUVR, particularly in the precuneus and cingulate cortices. Additionally, lower ventricular radioactivity (derived from amyloid-PET) showed strong negative associations in the dorsal apex of the neocortex. However, when all three ventricular parameters were included in the same model, these effects were mediated by ventricular volume. By contrast, the effect of the ventricular parameters on tau load was mediated by Aβ in the neocortex. Therefore, ventricular enlargement appears to be associated with Aβ load. Distinct from neurodegeneration, changes in ventricular parameters, particularly ventricular volume, are associated with upstream Alzheimer’s disease pathophysiology. While ventricular volume significantly mediated ventricular amyloid clearance, no such effect was observed for tau, suggesting distinct clearance mechanisms for these pathologies in Alzheimer’s disease.
- 3 March 2026
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (2)
Open AccessVentricular enlargement is associated with early Alzheimer’s disease pathophysiology
Alzheimer’s disease (AD) is characterized by progressive brain changes, including protein aggregation and structural changes. Cerebrospinal fluid (CSF) system abnormalities, such as ventricular dilation, increased choroid plexus volume or positron emission tomography (PET) ligand uptake in the CSF, have also been consistently described. We aimed to examine whether changes in CSF production and clearance might be associated with brain protein aggregation across biological stages of Alzheimer’s disease. We hypothesized an association between brain protein aggregation and changes on the CSF system. We examined 378 individuals from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort with T1-weighted magnetic resonance imaging (MRI), amyloid-PET and tau-PET assessments. We assessed the lateral ventricle and choroid plexus volumes, both corrected for intracranial volume, in the MRI native space. Non-specific ventricular tracer standardized uptake value ratio (SUVR), derived from amyloid- and tau-PET images, was used as an indirect marker of choroid plexus-related clearance activity and served as a metric of CSF dynamics. Linear models tested associations amongst lateral ventricular volume (reflecting CSF space enlargement), choroid plexus volume (reflecting secretory tissue morphology) and ventricular SUVR (reflecting tracer activity within the CSF compartment and serving as an indirect marker of choroid plexus-related clearance function and CSF dynamics) with Aβ and tau aggregations. Analyses were restricted to within-modality associations, relating ventricular radioactivity to cortical pathology for each PET tracer. We found that when considered independently, larger ventricular and choroid plexus volumes were associated with higher neocortical Aβ-PET SUVR, particularly in the precuneus and cingulate cortices. Additionally, lower ventricular radioactivity (derived from amyloid-PET) showed strong negative associations in the dorsal apex of the neocortex. However, when all three ventricular parameters were included in the same model, these effects were mediated by ventricular volume. By contrast, the effect of the ventricular parameters on tau load was mediated by Aβ in the neocortex. Therefore, ventricular enlargement appears to be associated with Aβ load. Distinct from neurodegeneration, changes in ventricular parameters, particularly ventricular volume, are associated with upstream Alzheimer’s disease pathophysiology. While ventricular volume significantly mediated ventricular amyloid clearance, no such effect was observed for tau, suggesting distinct clearance mechanisms for these pathologies in Alzheimer’s disease.
- Open Access
- 27 February 2026
- Published by Springer Nature in Research Square
Distinct molecular trajectories precede amyloid-β and tau pathology in Alzheimer’s disease
Alzheimer’s disease (AD) progresses over a prolonged preclinical phase marked by early amyloid-β pathology (Aβ), followed by tau spread and neurodegeneration. However, limited understanding of longitudinal, stage-specific molecular processes constrains therapeutic timing and patient stratification. Here, we reconstructed molecular trajectories across the AD continuum by integrating longitudinal cerebrospinal fluid (CSF) proteomics with Aβ and tau biomarkers from two independent cohorts. We identified distinct trajectories emerging prior to Aβ and tau conversion. Preclinical Aβ-dominated transitions were characterized by immune- and lipid-associated programs, whereas tau-dominated transitions at the mild cognitive impairment stage were linked to synaptic, proteostatic, and autophagy-related signatures. These stage-specific trajectories predicted biomarker conversion, including from the preclinical, pre-Aβ stage. Longitudinal voxelwise analyses further revealed spatially distinct cortical Aβ and tau patterns corresponding to inflammatory and proteostatic-synaptic signatures. Together, these findings define temporally ordered molecular pathways underlying AD progression and inform stage-specific therapeutic strategies.
- 27 February 2026
- Published by Springer Nature in Research Square
Open AccessDistinct molecular trajectories precede amyloid-β and tau pathology in Alzheimer’s disease
Alzheimer’s disease (AD) progresses over a prolonged preclinical phase marked by early amyloid-β pathology (Aβ), followed by tau spread and neurodegeneration. However, limited understanding of longitudinal, stage-specific molecular processes constrains therapeutic timing and patient stratification. Here, we reconstructed molecular trajectories across the AD continuum by integrating longitudinal cerebrospinal fluid (CSF) proteomics with Aβ and tau biomarkers from two independent cohorts. We identified distinct trajectories emerging prior to Aβ and tau conversion. Preclinical Aβ-dominated transitions were characterized by immune- and lipid-associated programs, whereas tau-dominated transitions at the mild cognitive impairment stage were linked to synaptic, proteostatic, and autophagy-related signatures. These stage-specific trajectories predicted biomarker conversion, including from the preclinical, pre-Aβ stage. Longitudinal voxelwise analyses further revealed spatially distinct cortical Aβ and tau patterns corresponding to inflammatory and proteostatic-synaptic signatures. Together, these findings define temporally ordered molecular pathways underlying AD progression and inform stage-specific therapeutic strategies.
- Open Access
- 8 February 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (7) , 1841-1856
Quantitative susceptibility mapping of the brain is associated with inflammatory changes in Alzheimer’s disease related areas
Accumulation of paramagnetic substances in brain tissue may constitute a feature of Alzheimer’s disease (AD) associated with inflammatory processes. This study employed MRI quantitative susceptibility mapping (QSM), as an index of paramagnetic load, to assess its association with brain Aβ and tau aggregates, as well as inflammatory biomarkers. We assessed QSM and T1-weighted MRI scans from 315 participants in the TRIAD cohort, including young-controls and individuals across the AD spectrum. Imaging was performed at baseline, with follow-up assessments at 12 and 24 months. Mean-cortical and subcortical susceptibility values were measured, and correlations with AD-relevant plasma and CSF inflammatory biomarkers. At baseline, AD patients had significantly greater QSM than age-matched controls in the posterior cingulate cortex, precuneus, and basal ganglia. After 24 months, QSM increased in the anterior cingulate in MCI, while dementia cases showed increase in the pallidum and hippocampus. Multiple comparison analysis indicated correlation between QSM and immune biomarkers IL-10RB, PD-L1, SCF, TWEAK, CSF-1, CXCL9, HGF, and CD40, but not with brain Aβ or tau-related biomarkers. Our findings reveal that the magnitude of tissue susceptibility load, as measured by QSM, reflects tissue inflammation rather than protein aggregation. QSM provides new insights into tissue dysfunction, with potential applications in AD therapeutic development.
- 8 February 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (7) , 1841-1856
Open AccessQuantitative susceptibility mapping of the brain is associated with inflammatory changes in Alzheimer’s disease related areas
Accumulation of paramagnetic substances in brain tissue may constitute a feature of Alzheimer’s disease (AD) associated with inflammatory processes. This study employed MRI quantitative susceptibility mapping (QSM), as an index of paramagnetic load, to assess its association with brain Aβ and tau aggregates, as well as inflammatory biomarkers. We assessed QSM and T1-weighted MRI scans from 315 participants in the TRIAD cohort, including young-controls and individuals across the AD spectrum. Imaging was performed at baseline, with follow-up assessments at 12 and 24 months. Mean-cortical and subcortical susceptibility values were measured, and correlations with AD-relevant plasma and CSF inflammatory biomarkers. At baseline, AD patients had significantly greater QSM than age-matched controls in the posterior cingulate cortex, precuneus, and basal ganglia. After 24 months, QSM increased in the anterior cingulate in MCI, while dementia cases showed increase in the pallidum and hippocampus. Multiple comparison analysis indicated correlation between QSM and immune biomarkers IL-10RB, PD-L1, SCF, TWEAK, CSF-1, CXCL9, HGF, and CD40, but not with brain Aβ or tau-related biomarkers. Our findings reveal that the magnitude of tissue susceptibility load, as measured by QSM, reflects tissue inflammation rather than protein aggregation. QSM provides new insights into tissue dysfunction, with potential applications in AD therapeutic development.
- Open Access
- 20 January 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (8) , 2803-2815
Clinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data
Alzheimer's disease (AD) is defined by its characteristic neuropathological changes, which allow for diagnosis and assessment of severity. Recently, the Alzheimer's Association proposed a framework to stage AD biologically based on tau-PET. Furthermore, the framework hypothesizes a degree of alignment between biological AD severity and clinical symptom severity. We aimed to investigate the concordance between clinical and biological stages of AD and explore factors contributing to discordance using in vivo and post-mortem neuropathological data. Data from 768 amyloid-β-positive individuals were drawn from four observational cross-sectional in vivo cohorts (TRIAD, ADNI, HABS-HD and SCAN) in addition to a post-mortem autopsy dataset from the National Alzheimer's Coordinating Center (NACC; n = 3188). All in vivo participants had tau-PET imaging, clinical diagnosis and neurobehavioural assessments. Participants were assigned a biological AD stage based on their tau-PET scan according to the Alzheimer's Association revised criteria stages. The autopsy dataset included individuals with moderate-to-frequent neuritic plaques (CERAD scores 2–3), along with pre-mortem clinical and neurobehavioural data. Clinical–biological concordance was quantified using squared-weighted Cohen's κ. Ordinal and linear regression models assessed associations between biological stage and clinical severity (Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Examination), adjusting for age, sex and cohort. Post-mortem analyses evaluated the impact of comorbid neuropathologies on clinical–biological discordance using adjusted odds ratios and ordinal regression. Overall concordance between clinical and biological AD staging was moderate (Cohen's κ = 0.52, P < 0.001). Approximately 70% of individuals classified as cognitively unimpaired or with dementia exhibited biological stages consistent with their clinical diagnoses. In contrast, transitional decline and mild cognitive impairment groups were more heterogeneous. Notably, 25% of amyloid-β-positive individuals with mild cognitive impairment demonstrated no detectable tau-PET abnormality. Nonetheless, advanced tau-PET stage was reliably associated with clinical impairment. In the NACC autopsy dataset, nearly all individuals with a more severe clinical stage than their proposed biological stage exhibited comorbid neuropathologies, including frontotemporal lobar degeneration (FTLD)-TDP-43, FTLD-tau, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and cerebrovascular disease. The number of comorbid pathologies was strongly associated with increased odds of clinical dementia (t = 8.45, P < 0.001). Although there is moderate agreement between clinical and biological stages of AD across the entire disease spectrum, strong agreement is found in clinically unimpaired and dementia stages. Comparison of clinical and biological AD stages provides a framework for understanding the large contributions of non-AD neurodegenerative diseases to dementia in amyloid-β-positive individuals. Our results have important implications for clinical trial recruitment strategies and highlight the urgent need for biomarkers for non-AD pathological processes.
- 20 January 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (8) , 2803-2815
Open AccessClinical–biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data
Alzheimer's disease (AD) is defined by its characteristic neuropathological changes, which allow for diagnosis and assessment of severity. Recently, the Alzheimer's Association proposed a framework to stage AD biologically based on tau-PET. Furthermore, the framework hypothesizes a degree of alignment between biological AD severity and clinical symptom severity. We aimed to investigate the concordance between clinical and biological stages of AD and explore factors contributing to discordance using in vivo and post-mortem neuropathological data. Data from 768 amyloid-β-positive individuals were drawn from four observational cross-sectional in vivo cohorts (TRIAD, ADNI, HABS-HD and SCAN) in addition to a post-mortem autopsy dataset from the National Alzheimer's Coordinating Center (NACC; n = 3188). All in vivo participants had tau-PET imaging, clinical diagnosis and neurobehavioural assessments. Participants were assigned a biological AD stage based on their tau-PET scan according to the Alzheimer's Association revised criteria stages. The autopsy dataset included individuals with moderate-to-frequent neuritic plaques (CERAD scores 2–3), along with pre-mortem clinical and neurobehavioural data. Clinical–biological concordance was quantified using squared-weighted Cohen's κ. Ordinal and linear regression models assessed associations between biological stage and clinical severity (Clinical Dementia Rating-Sum of Boxes, Mini-Mental State Examination), adjusting for age, sex and cohort. Post-mortem analyses evaluated the impact of comorbid neuropathologies on clinical–biological discordance using adjusted odds ratios and ordinal regression. Overall concordance between clinical and biological AD staging was moderate (Cohen's κ = 0.52, P < 0.001). Approximately 70% of individuals classified as cognitively unimpaired or with dementia exhibited biological stages consistent with their clinical diagnoses. In contrast, transitional decline and mild cognitive impairment groups were more heterogeneous. Notably, 25% of amyloid-β-positive individuals with mild cognitive impairment demonstrated no detectable tau-PET abnormality. Nonetheless, advanced tau-PET stage was reliably associated with clinical impairment. In the NACC autopsy dataset, nearly all individuals with a more severe clinical stage than their proposed biological stage exhibited comorbid neuropathologies, including frontotemporal lobar degeneration (FTLD)-TDP-43, FTLD-tau, Lewy bodies, limbic-predominant age-related TDP-43 encephalopathy (LATE) and cerebrovascular disease. The number of comorbid pathologies was strongly associated with increased odds of clinical dementia (t = 8.45, P < 0.001). Although there is moderate agreement between clinical and biological stages of AD across the entire disease spectrum, strong agreement is found in clinically unimpaired and dementia stages. Comparison of clinical and biological AD stages provides a framework for understanding the large contributions of non-AD neurodegenerative diseases to dementia in amyloid-β-positive individuals. Our results have important implications for clinical trial recruitment strategies and highlight the urgent need for biomarkers for non-AD pathological processes.